Leerink Partners Remains a Buy on Castle Biosciences (CSTL)

In a report issued on April 4, Puneet Souda from Leerink Partners maintained a Buy rating on Castle Biosciences (CSTLResearch Report). The company’s shares closed last Tuesday at $38.40, close to its 52-week low of $31.46.

According to, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.5% and a 41.0% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Twist Bioscience, and Myriad Genetics.

Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $73.25, representing a 59.3% upside. In a report issued on April 4, Robert W. Baird also maintained a Buy rating on the stock with a $60.00 price target.

See today’s best-performing stocks on TipRanks >>

Castle Biosciences’ market cap is currently $1.17B and has a P/E ratio of -37.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Read More on CSTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More